Cimzia (certolizumab pegol) / UCB, Ferring, Astellas 
Welcome,         Profile    Billing    Logout  

38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimzia (certolizumab pegol) / Astellas, UCB
2015-002284-42: The rationale for this study is to gain insight in the extent and impact of immunogenicity of TNF inhibitors in the European daily clinical practice. Furthermore, an European wide database will give insight in factors influencing immunogenicity and treatment outcome in terms of disease activit

Ongoing
4
1650
Europe
etanercept, adalimumab, certolizumab pegol, golimumab, infliximab, Injection, Infusion, Enbrel, Humira, Cimzia, Simponi, Remicade
READE, PFIZER
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis., Not possible to specify
 
 
2012-004482-40: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluación de un protocolo para la disminución de dosis en pacientes con Artritis Reumatoide (AR) en remisión clínica en tratamiento con terapias biológicas

Ongoing
4
28
Europe
Infliximab, Adalimumab, Etanercept, Certolizumab Pegol, Golimumab, Abatacept, Tocilizumab, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra, HUMIRA, ENBREL, CIMZIA, SIMPONI, ORENCIA, RoActemra
FRANCISCO J. BLANCO GARCÍA, FRANCISCO J. BLANCO GARCIA
Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies Evaluación de la utilidad clínica de un protocolo estandarizado de estrategias para la disminución de dosis en pacientes con Artritis Reumatoide en remisión clínica a tratamiento con terapias biológicas
 
 
2007-005464-26: Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body.

Ongoing
4
100
Europe
Cimzia, Remicade, Enbrel, Humira, Cimzia, Remicade, Enbrel, Humira, Cimzia
Kings College London, Guys and St Thomas\'NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust BRC
Rheumatoid Arthritis
 
 
2016-003129-40: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide

Ongoing
4
60
Europe
HUMIRA (ADALIMUMAB), CIMZIA (Certolizumab Pegol), ENBREL (Etanercept), REMICADE (INFLIXIMAB), SIMPONI (GOLIMUMAB), [NA], [-], Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER, CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL, ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ, REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV, SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AIFA - Italian Medicines Agency
RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), RHEUMATOID ARTHRITIS (RA) PATIENTS PAZIENTI AFFETTI DA ARTRITE REUMATOIDE (AR), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2016-004300-65: Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFα) blocking Agent by immunoscintigraphy with Technetium-labeled Cimzia®).

Ongoing
4
120
Europe
99mTc-S-HYNIC Certolizumab pegol, Solution for injection
Ghent University Hospital, UCB Pharma SA
rheumatoid arthritis, rheumatoid arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial

Ongoing
4
180
Europe
Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita
MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland
Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis.

Ongoing
4
234
Europe
Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab
Sint Maartenskliniek, Sint Maartenskliniek
Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20]
 
 
NORD-STAR, NCT01491815 / 2011-004720-35: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Active, not recruiting
4
812
Europe, RoW
Non-biological DMARD's, Cimzia, Orencia, RoActemra
Karolinska Institutet
Rheumatoid Arthritis
07/23
12/23
NCT02466581 / 2014-002374-36: Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Active, not recruiting
4
25
Europe
Sulphasalazine + Hydroxychloroquine OR Prednisolone, SSZ+HCQ or Prednisolone, Cimzia, Certolizumab-pegol, Orencia, Abatacept, RoActemra, Tocilizumab
Karolinska Institutet
Rheumatoid Arthritis
07/23
12/23
BIOTAPE, NCT05115903: Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Active, not recruiting
4
15
Canada
Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks
University Health Network, Toronto
Axial Spondyloarthritis
07/24
08/24
COVER, NCT05080218: COVID-19 VaccinE Response in Rheumatology Patients

Recruiting
4
1000
US
Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz
Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
02/24
09/24
2013-000337-13: Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA) Vorhersage des Ansprechens von Certolizumab Pegol mittels Bildgebung des Gehirns. Eine multicenter, randomisierte doppel-blind Studie. Vorhersage des Ansprechens von Certolizumab-Pegol in der Rheumatoiden Arthritis (PreCePra)

Ongoing
3
156
Europe
Cimzia, Suspension for injection in pre-filled syringe, Cimzia
Universitätsklinikum Erlangen, UCB Pharma SA
Patients with active Rheumatoid Artrhitis (DAS28 > 3.2) despite DMARD therapy Patienten mit einer aktiver Rheumatoiden Arthritis (DAS28 > 3.2) trotz Therapie mit DMARD, s, RA patients DMARD -IR RA Patienten DMARD-Versager, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2007-003239-21: A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home

Ongoing
3
150
Europe
Certolizumab pegol, CDP870,
UCB PHARMA S.A.
Crohn\'s disease
 
 
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms

Not yet recruiting
3
270
Europe
Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung
Universitätsklinikum Erlangen, Universitätsklinikum Erlangen
Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20]
 
 
2021-005309-28: Effectiveness of certolizumab in women with unexplained recurrent implantation failure Efficacité du certolizumab chez les femmes présentant un échec d'implantation à répétition inexpliqué

Ongoing
3
161
Europe
CIMZIA 200 mg, Solution for injection in pre-filled syringe, CIMZIA® 200 mg
Assistance Publique des Hôpitaux de Paris, DGOS
Adult women with recurrent implantation failures Femmes adultes présentant des échecs d'implantation récurrents, correct immunological abnormalities and increase the pregnancy rate corriger les anomalies immunologiques et augmenter le taux de grossesse, Body processes [G] - Reproductive physiologi cal processes [G08]
 
 
SYBRA, NCT05379322: The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn
3
145
RoW
Anti-TNF, Adalimumab, etanercept, certolizumab, or golimumab, JAK inhibitor, Tofacitinib, baricitinib, or upadacitinib
Abu Dhabi Stem Cells Center
Rheumatoid Arthritis
10/23
04/24
NCT01550003: Pediatric Arthritis Study of Certolizumab Pegol

Checkmark For juvenile idiopathic arthritis
Dec 2016 - Dec 2016: For juvenile idiopathic arthritis
Completed
3
193
Canada, US, RoW
Certolizumab Pegol (CZP), Cimzia
UCB BIOSCIENCES GmbH, PRA Health Sciences
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
04/24
04/24
CIMcare, NCT04123795: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Recruiting
3
150
Canada, US
Certolizumab pegol, Placebo
UCB Biopharma SRL
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
09/29
08/34
NCT04610476: Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Recruiting
3
270
Europe
Prednisolone, Prednisolone generic drugs, Sulfasalazine, Azulfidine, Leflunomide, Arava, Methotrexate, Lantarel, Metex, Tofacitinib, Xeljanz, Apremilast, Otezla, Etanercept, Enbrel, Erelzi, Benepali, Adalimumab, Humira, Amgevita, Imraldi, Hyrimoz, Infliximab, Remicade, Zessly, Inflectra, Certolizumab pegol, Cimzia, Golimumab, Simponi, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Ustekinumab, Stelara
University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Withdrawal, Reduction
10/24
10/25
NCT03414502: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
3
400
US
Methotrexate, Methotrexate (MTX), Abatacept, Orencia, Adalimumab, Humira, Azathioprine, Imuran, Baricitinib, Olimuant, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Hydroxychloroquine, Plaquenil, Infliximab, Remicade, Leflunomide, Arava, Minocycline, Minocin, Rituximab, Rituxin, Sarilumab, Kevzara, Sulfasalazine, Azulfidine, Tofacitinib, Xeljanz
University of Nebraska
Rheumatoid Arthritis
03/26
03/28
CERTIFY, NCT05930613 / 2021-005309-28: Certolizumab in Recurrent Implantation Failure (RIF)

Recruiting
3
161
Europe
Certolizumab (CIMZIA® ; TNF-α antagonist), Placebo (NaCl 0.9 % solution)
Assistance Publique - Hôpitaux de Paris, DGOS
Recurrent Unexplained Implantation Failure
04/29
04/29
2020-001177-78: Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with Antiphospholipid syndrome (APS) or systemic lupus erythematosus (SLE) Certolizumab en prévention de complications de la grossesse chez les patientes à haut risque atteintes d’un Syndrome des Antiphospholipides (SAPL) et/ou d’un Lupus Erythémateux Systémique et porteuse de l’anticorps Anticoagulant circulant (ACC) de type lupique

Not yet recruiting
2
50
Europe
Certolizumab, Solution for injection in pre-filled syringe, CIMZIA
University of Utah, University of Utah
Pregnant women with Antiphospholipid Syndrom (APS) and Lupus Antocoagulant (LAC) Patientes enceintes atteintes d’un Syndrome des Antiphospholipides (SAPL) et/ou d’un Lupus Erythémateux Systémique et porteuse de l’anticorps Anticoagulant circulant (ACC) de type lupique, Pregnant women with Antiphospholipid Syndrom (APS) and Lupus Antocoagulant (LAC) Patientes enceintes atteintes d’un Syndrome des Antiphospholipides (SAPL) et/ou d’un Lupus Erythémateux Systémique et porteuse de l’anticorps Anticoagulant circulant (ACC) de type lupique, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
DAISY, NCT06028438: A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Active, not recruiting
2
104
Europe, US, RoW
Placebo, Nipocalimab, JNJ-80202135, M281, Certolizumab, Cimzia
Janssen Research & Development, LLC
Arthritis, Rheumatoid
09/24
11/24
NCT04991025: Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Recruiting
2
60
US
Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab
Memorial Sloan Kettering Cancer Center
Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
10/24
10/24
NCT03152058: IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Recruiting
2
55
Canada, US
Certolizumab Pegol, Cimzia
David Ware Branch, Hospital for Special Surgery, New York, University of Toronto, NYU Langone Health
High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
12/24
12/25
CHERISH, NCT04163016: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Completed
1b
22
Europe, US
Pharmacokinetics of certolizumab pegol, PK
UCB Biopharma SRL
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
05/23
05/23
TICIMEL, NCT03293784: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

Completed
1
33
Europe
Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab, Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
Institut Claudius Regaud
Melanoma
12/19
08/23
NCT02714881: Lipids, Inflammation, and CV Risk in RA

Completed
N/A
76
US
certolizumab, Cimzia, Stress myocardial perfusion PET, Cardiac PET
Brigham and Women's Hospital
Rheumatoid Arthritis, Cardiovascular Disease
05/21
08/23
NCT04569890: Treatment of Pregnancy RA

Not yet recruiting
N/A
100
RoW
Certolizumab Pegol 200 MG/ML [Cimzia], Hydroxychloroquine, Prednisone
RenJi Hospital
Rheumatoid Arthritis, Pregnancy Related
12/22
12/23
NCT03559660: CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

Available
N/A
NA
Certolizumab Pegol, Cimzia
UCB Biopharma SRL
Crohn's Disease
 
 
NCT03559686: Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

Available
N/A
NA
Certolizumab Pegol, Cimzia
UCB Biopharma SRL
Rheumatoid Arthritis
 
 
NCT01797224: OTIS Autoimmune Diseases in Pregnancy Project

Recruiting
N/A
925
US
University of California, San Diego, The Organization of Teratology Information Specialists, UCB Pharma
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
09/23
10/26
NCT05119452: Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

Not yet recruiting
N/A
85
NA
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD), b/tsDMARD: Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Tocilizumab, Sarilumab, Etanercept, Anakinra, Filgotinib, Updacitinib, Tofacitinib, Baricitinib
Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Hospital Hietzing, Krankenhaus Bruneck
Rheumatoid Arthritis
09/24
09/24
SUPRA, NCT05305066: Stand UP to Rheumatoid Arthritis

Recruiting
N/A
75
Canada
TNFi, Etanercept, Adalimumab, Golimumab, Certolizumab, Anti-IL6, Tocilizumab, Sarilumab, JAKi, Tofacitinib, Upadacitinib, Baricitinib
Marie Hudson, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal General Hospital, Lady Davis Institute
Rheumatoid Arthritis
12/25
12/26
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting
N/A
240
Europe
Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab
Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb
Ulcerative Colitis
01/25
01/25
NeuMRA, NCT04378621: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients

Active, not recruiting
N/A
212
Europe
TNF-α inhibitor OR JAK inhibitor, TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz), Hand training, physiotherapy of hands
Vastra Gotaland Region
Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline, Depression, Brain Diseases, Hand Rheumatism
09/25
09/25
CHOIR, NCT04725422: CHronic Nonbacterial Osteomyelitis International Registry

Recruiting
N/A
2000
US
Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
Seattle Children's Hospital, Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York City, NY, USA, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University
Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
08/28
08/50
NCT05651373: The Clinical Features and Pregnancy Outcomes of RA Patients

Recruiting
N/A
100
RoW
Prednisone, Pred, Hydroxychloroquine, HCQ, CertolizumabPegol injection, Cimzia
Qilu Hospital of Shandong University
Rheumatoid Arthritis, Pregnancy Related
08/23
12/24

Download Options